Garrick P. Smith

Copenhagen, 2500, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Development of 18F/11C-Labeled Pyrrolo-Pyridine/Pyrimidine LRRK2 Selective PET Radioligands.

Development of 18F/11C-Labeled Pyrrolo-Pyridine/Pyrimidine LRRK2 Selective PET Radioligands.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 01, 2025

Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate.

Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate.

Journal: Journal of medicinal chemistry

Published: June 29, 2021

Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.

Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.

Journal: eNeuro

Published: November 19, 2018

A genetic risk score for hypertension is associated with risk of thoracic aortic aneurysm.

A genetic risk score for hypertension is associated with risk of thoracic aortic aneurysm.

Journal: Journal of human hypertension

Published: August 20, 2018

Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.

Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.

Journal: Neurobiology of disease

Published: February 01, 2018

PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.

PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.

Journal: Toxicology

Published: November 23, 2017

Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).

Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).

Journal: Journal of medicinal chemistry

Published: October 13, 2017

The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors.

The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: June 13, 2017

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Journal: Scientific reports

Published: April 27, 2017

Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

Journal: Progress in medicinal chemistry

Published: March 19, 2017

Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity.

Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity.

Journal: Frontiers in cellular neuroscience

Published: February 25, 2016

Asc-1 Transporter Regulation of Synaptic Activity via the Tonic Release of d-Serine in the Forebrain.

Asc-1 Transporter Regulation of Synaptic Activity via the Tonic Release of d-Serine in the Forebrain.

Journal: Cerebral cortex (New York, N.Y. : 1991)

Published: January 23, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026